Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
KYORIN Pharma Surges on License Agreement with France's Biodol for Neuropathic Pain Drug Candidate
KYORIN Pharmaceutical Co.,Ltd. <4569> rose sharply, rebounding for the first time in three days. After the close of trading on the 31st, the company announced it had signed a license agreement with French drug discovery venture Biodol Therapeutics for the neuropathic pain treatment drug candidate "BDT272," which is being viewed as positive news.
"BDT272" is a compound believed to exert effective analgesic effects by inhibiting FLT3 (receptor tyrosine kinase family), which is deeply involved in the onset and persistence of pain, including neuropathic pain. Under this license agreement, KYORIN Pharma has acquired exclusive development, manufacturing, and commercialization rights in Japan, South Korea, and Taiwan. In consideration, the company will pay Biodol up to 79 million euros in total as upfront payments and milestone payments, as well as royalties based on net sales.
Source: MINKABU PRESS
Related Articles
Stock in Focus: FRONTIER INTERNATIONAL's Organic Subsidiaries Show Improved Profitability
Sumasapo extends gains on acquisition of municipal solution business from T&C Technologies
CERES INC. continues to rise on announcement of subsidiary acquisition of online medical consultation platform operator SQUIZ
MCJ shares fall sharply for first time in 4 days as Bain Capital states no intention to raise TOB price
MIRAINI Holdings Surges on Planned \8.8 Billion Negative Goodwill Gain in Q1 FY03/27
GNI Group surges after three-day decline on forecast of consecutive record-high sales for December 2026
Minkabu Individual Investor Sentiment: Tokio Marine Ranks 4th in Rising Sell Predictions
Investment Money Flows into Defense-Related Stocks Including Mitsubishi Heavy as Global Geopolitical Risks Intensify, Triggering Fresh Buying
Nxera Pharma surges again, briefly hitting daily limit as partner Centessa to be acquired by Eli Lilly
JELLY BEANS Continues to Rise on Plans to Establish SPC for Recycled Heavy Oil Refinery Business Through Subsidiary